Sobel Mark E, Dreyfus Jennifer C
American Society for Investigative Pathology, Bethesda, Maryland.
Dreyfus Consulting, LLC, Takoma Park, Maryland.
Am J Pathol. 2017 Jan;187(1):4-8. doi: 10.1016/j.ajpath.2016.11.001. Epub 2016 Dec 1.
Academic pathology departments will be dramatically affected by proposed United States federal government regulatory initiatives. Pathology research will be substantially altered if proposed changes to the Common Rule (Code of Federal Regulations: Protection of Human Subjects title 45 CFR 46) and regulations governing the return of individual research results are approved and finalized, even more so now that the Precision Medicine initiative has been launched. Together, these changes are disruptive influences on academic pathology research as we know it, straining limited resources and compromising advances in diagnostic and academic pathology. Academic research pathologists will be challenged over the coming years and must demonstrate leadership to ensure the continued availability of and the ethical use of research pathology specimens.
美国联邦政府提出的监管举措将对学术病理部门产生巨大影响。如果对《通用规则》(《联邦法规法典:保护人类受试者》第45 CFR 46编)以及关于返还个体研究结果的规定所提议的修改获得批准并最终确定,那么病理学研究将会发生重大改变,更何况现在精准医学计划已经启动。总之,正如我们所知,这些变化对学术病理研究产生了颠覆性影响,使有限的资源紧张,并危及诊断病理学和学术病理学的进展。在未来几年里,学术研究病理学家将面临挑战,必须发挥领导作用,以确保研究病理标本的持续供应以及合乎伦理地使用。